RenovoRx Statistics
Share Statistics
RenovoRx has 36.55M
shares outstanding. The number of shares has increased by 48.49%
in one year.
| Shares Outstanding | 36.55M |
| Shares Change (YoY) | 48.49% |
| Shares Change (QoQ) | 48.18% |
| Owned by Institutions (%) | 4.06% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,551 |
| FTD / Avg. Volume | 3.53% |
Short Selling Information
The latest short interest is 250.26K, so 0.7% of the outstanding
shares have been sold short.
| Short Interest | 250.26K |
| Short % of Shares Out | 0.7% |
| Short % of Float | 0.71% |
| Short Ratio (days to cover) | 2.21 |
Valuation Ratios
The PE ratio is -3.26 and the forward
PE ratio is -4.08.
RenovoRx's PEG ratio is
0.16.
| PE Ratio | -3.26 |
| Forward PE | -4.08 |
| PS Ratio | 668.13 |
| Forward PS | 0.7 |
| PB Ratio | 6.42 |
| P/FCF Ratio | -3.14 |
| PEG Ratio | 0.16 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for RenovoRx.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.1,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.1 |
| Quick Ratio | 4.1 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $4,300 |
| Profits Per Employee | $-881,400 |
| Employee Count | 10 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -24.46% in the
last 52 weeks. The beta is 1.12, so RenovoRx's
price volatility has been higher than the market average.
| Beta | 1.12 |
| 52-Week Price Change | -24.46% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 57.62 |
| Average Volume (20 Days) | 100,491 |
Income Statement
In the last 12 months, RenovoRx had revenue of 43K
and earned -8.81M
in profits. Earnings per share was -0.4.
| Revenue | 43K |
| Gross Profit | 43K |
| Operating Income | -10.97M |
| Net Income | -8.81M |
| EBITDA | -10.97M |
| EBIT | -10.97M |
| Earnings Per Share (EPS) | -0.4 |
Full Income StatementBalance Sheet
The company has 7.15M in cash and 278K in
debt, giving a net cash position of 6.88M.
| Cash & Cash Equivalents | 7.15M |
| Total Debt | 278K |
| Net Cash | 6.88M |
| Retained Earnings | -50.22M |
| Total Assets | 8.12M |
| Working Capital | 5.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -9.13M
and capital expenditures -12K, giving a free cash flow of -9.14M.
| Operating Cash Flow | -9.13M |
| Capital Expenditures | -12K |
| Free Cash Flow | -9.14M |
| FCF Per Share | -0.41 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -25511.63% and -20497.67%.
| Gross Margin | 100% |
| Operating Margin | -25511.63% |
| Pretax Margin | -20497.67% |
| Profit Margin | -20497.67% |
| EBITDA Margin | -25511.63% |
| EBIT Margin | -25511.63% |
| FCF Margin | -21248.84% |
